Targeting Delivery of Chemotherapeutic Agents to Mammary Tumors
Abstract
Breast cancer is the second leading cause of cancer incidence and the leading cause of cancer mortality in women. Current chemotherapeutic treatments often have adverse effects primarily caused by the inefficient delivery and/or poor specificity of the compounds to breast tissues. Overall, we were interested in determining whether current therapeutic agents be redesigned to carry "tissue specific markers" to enhance their delivery and uptake in targeted tumor cells. In order to accomplish this goal, efficient delivery and increased specificity of chemotherapeutic agents to targeted cells must be achieved. Recently, researchers identified germline mutations in the tumor suppressor gene BRCA1 that predisposes women to early onset breast cancer. To recapitulate this condition, our laboratory generated a Brcal mouse model that selectively develops mammary tumors between 6-9 months of age. Using this Brca1 breast cancer model and cell lines derived from mammary tumors, phage display was used to isolate and identify peptide motifs that selectively bind to cultured Brcal mammary tumor cell lines. Next, the identified candidate peptides were conjugated to a tracer and tested for in vitro and in vivo efficiency and specificity of delivery toward mammary tumor cell lines and mammary tissues.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2001
- Accession Number
- ADA398692
Entities
People
- Steven G. Brodie
Organizations
- National Institutes of Health